Primary care physicians now have detailed guidance for treating five common psychiatric conditions in patients with autism spectrum disorder, according to new clinical guidelines.
The guidelines, developed by specialists at the Lurie Center for Autism at Massachusetts General Hospital, address medication management for sleep disturbances, attention-deficit/hyperactivity disorder (ADHD), anxiety, depression, and irritability in patients with autism spectrum disorder (ASD). The recommendations were created through iterative refinements and consensus from experienced clinicians, supplemented by a review of key clinical trials and literature to ensure relevance and accuracy.
"The current climate of ASD care absolutely requires that general practitioners receive the knowledge and training necessary to increase familiarity and comfort with ASD-specific prescribing practices, as referring to specialists for every case is no longer a sustainable model," Mariah A. Manter from the Lurie Center and colleagues wrote in an article published in BMC Medicine.
Standard-of-care treatments used in neurotypical patients often require modification for those with ASD. For anxiety and depression, buspirone and mirtazapine are preferred first-line medications over selective serotonin reuptake inhibitors (SSRIs), which can cause behavioral activation in ASD patients. SSRIs, such as fluoxetine, may exacerbate symptoms like impulsivity, hyperactivity, and decreased concentration due to their activating effects.
For ADHD, while stimulants are typically first-line for neurotypical patients, non-stimulants like α2-adrenergic agonists may be more suitable for many ASD patients. Similarly, sleep disturbances are often treated with melatonin, which improved sleep in over 84% of individuals in a meta-analysis, highlighting efficacy and tolerability.
The guidelines establish four core prescribing principles: "Start Low and Go Slow," "Monitoring Matters," "One Size Does Not Fit All," and "Back to the Basics." Regular check-ups are emphasized to monitor for side effects, especially given the atypical responses of ASD patients who may not communicate adverse effects effectively.
Of 8-year-olds, ASD prevalence impacts 1 in 36, as of 2020. The surge in cases has overwhelmed specialty clinics, creating an urgent need for general practitioners to manage routine ASD care.
The authors noted that medication choices often depend on co-occurring conditions. For example, in ASD patients with both ADHD and anxiety, α2-adrenergic agonists may be particularly beneficial as they can address both conditions.
For sleep disturbances, the guidelines recommend starting with sleep hygiene and melatonin, similar to neurotypical protocols. In cases of irritability, the α2-adrenergic agonist guanfacine is recommended before considering FDA-approved antipsychotics risperidone and aripiprazole.
The guidelines also detail specific dosing protocols, potential adverse effects, and monitoring requirements for each medication class. They emphasize the importance of considering individual patient factors like ability to swallow pills and tolerance for blood draws when selecting treatments.
For future research, the authors called for more randomized controlled trials of medications in ASD populations, noting that many current prescribing practices are based on clinical experience rather than robust trial data.
These guidelines represent one of the first comprehensive efforts to provide practical, evidence-based psychopharmacology guidance specifically tailored for treating psychiatric conditions in ASD patients within primary care settings.
The authors acknowledge study limitations, including that recommendations are based on consensus among prescribers from a single institution who may share similar clinical training and experiences.
The guidelines are intended to support primary care physicians in making informed decisions when prescribing medications for ASD patients with co-occurring psychiatric and behavioral conditions, ultimately enhancing access to timely, comprehensive care for all individuals with ASD.
Conflict of interest disclosures can be found in the study.
